| Document |
Document Title |
|
JP6273258B2 |
Compounds of the formula (I), in which R1, R3, R5, R6, R7, R, X and Y have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
|
|
JP2018002741A |
To provide a protein receptor tyrosine kinase inhibitor.The present invention relates to a novel synthesis substituted heterocyclic compound and pharmaceutical composition containing the same that can inhibit or antagonize a receptor tyr...
|
|
JP2017218444A |
To provide a novel compound and a herbicide prepared using the same.The present invention provides a ketone or oxime compound represented by formula (1) [B is B-1, B-2 or B-3; Q is O, NORor the like; m and n are an integer of 0-2; R, R, ...
|
|
JP6243340B2 |
Methods for producing lactams from oximes by performing a Beckmann rearrangement using a silicoaluminophosphate catalyst are provided. These catalysts may be used in gas phase or liquid phase reactions to convert oximes into lactams. Hig...
|
|
JP6231621B2 |
An object of the present invention is to provide a compound having a V2 receptor agonistic activity. Provided is a pharmaceutical composition which contains, as an active ingredient, a compound represented by the general formula (I) desc...
|
|
JP2017200906A |
To provide a method for producing lactam from oxime.A method for performing a gas-phase reaction or a liquid-phase reaction for converting oxime to lactam by Beckmann rearrangement in the presence of a silicoaluminophosphate catalyst hav...
|
|
JP6226437B2 |
The purpose of the present invention is to provide a pharmaceutical composition that is useful for the treatment of diseases that are caused by an increase in bone resorption and that does not cause serious side effects even when used in...
|
|
JPWO2016199706A1 |
A control circuit that controls a current from a power supply source, a cooling means that can cool the surroundings by the flow of a refrigerant, a heat transfer means that connects the cooling means and the control circuit, and the hea...
|
|
JP6215212B2 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including,e.g., in the treatment or prevention of cancer, a ne...
|
|
JP6215958B2 |
|
|
JP2017178965A |
To provide a crystalline form of the ivabradine hydrochloride, which has constant physical properties, has novelty, and is thermodynamically stable and pure.This invention relates to a method for preparing ivabradine hydrochloride form I...
|
|
JP6192027B2 |
Provided are compounds of formula (II) useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compounds have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease,...
|
|
JP2017522388A |
The present disclosure provides compositions and methods for selectively killing senescent cells, the composition comprising piperlongmin (PL) or a derivative thereof. Selective killing of senescent cells can delay aging and / or treat a...
|
|
JPWO2016059942A1 |
A device installed between a three-phase AC power supply and a group of light-emitting diodes, which is a three-phase full bridge circuit in which a pair of switching elements are connected in parallel between the three-phase DC bus of t...
|
|
JP6169737B2 |
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. X in formula (I) is selected from -OCF 3 and -OCH 3 . The other variables for Structural Formula (I) ar...
|
|
JP6165748B2 |
Compounds of the general structure S-1, wherein X and R1-R5 are defined in the specification, are capable of abrogating the deubiquitinating (DUB) activity of the 19S RP DUBs and are useful in methods and compositions for treating cancer...
|
|
JP2017514848A |
The present invention relates to hemipamoart of ivabrazine represented by the formula (I) and a hydrate thereof. The present invention also relates to drugs.
|
|
JP6141428B2 |
Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3 and R4 are described in this application, and methods of using said compounds in the treatment of cancer.
|
|
JP6119022B2 |
|
|
JPWO2015146053A1 |
Provided are a nonionic photoacid generator containing an imide sulfonate compound having high photosensitivity to i-rays, excellent heat stability, and excellent solubility in hydrophobic materials, and a resin composition for photolith...
|
|
JP6112659B2 |
|
|
JP6105585B2 |
Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following ...
|
|
JP2017507962A |
A tricyclic chemical modulator of protein phosphatase 2A is disclosed. This compound is effective in treating tumors, age-onset protein toxicity, stress-induced depression, inflammation, and acne. This compound belongs to the following p...
|
|
JP6097765B2 |
The present invention relates to phenyl-substituted heterocyclyl derivatives of the formula (I), wherein Z, n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as described in the description and their use as prostaglandin receptor modulators, m...
|
|
JP6089286B2 |
Provided is a mononuclear ruthenium complex that comprises a ruthenium-silicon bond that is represented by formula (1) and that exhibits excellent catalyst activity in each of a hydrosilylation reaction, a hydrogenation reaction, and red...
|
|
JP6085892B2 |
Provided is a mononuclear iron complex that comprises an iron-silicon bond that is represented by formula (1) and that exhibits excellent catalyst activity in each of a hydrosilylation reaction, a hydrogenation reaction, and reduction of...
|
|
JPWO2014174745A1 |
The water-soluble polycyclic compound of the present invention or a pharmacologically acceptable salt thereof has a large solubility in an aqueous solvent and has a large solubility in an aqueous solvent as compared with a conventional E...
|
|
JPWO2014157020A1 |
In the method of oxidizing an amine to produce an oxime, a first contact step and a second contact step are included, and the second contact step is further carried out in the presence of at least a part of the oxidation product obtained...
|
|
JP2017504626A |
Provided herein are compounds useful for the treatment of HBV infection in subjects in need thereof, their pharmaceutical compositions and methods of inhibiting, suppressing or preventing HBV infection in subjects.
|
|
JP6061923B2 |
A compound useful for the preparation of building blocks for the manufacture of various compounds is represented by Formula 2a:
|
|
JP6058519B2 |
Process (P1) for synthesizing (2E)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile (I), comprises subjecting 4-bromo-1,2-dimethoxybenzene (II) to a coupling reaction with acrylonitrile in the presence of a palladium catalyst, a ligand, a base a...
|
|
JP2017002070A |
To provide compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8.The present invention provides a compound of formula I or pharmaceutically acceptable salt thereof [R-Rand R-Rindepen...
|
|
JP2016222570A |
To provide a compound that has 5-HT2C receptor agonist activity and is useful as a therapeutic agent or a preventive agent for stress urinary incontinence.The present invention provides an azepane derivative represented by the following ...
|
|
JP6030397B2 |
|
|
JP6006634B2 |
To provide a method for producing epinastine via a new intermediate which is safely synthesizable at a low cost.Epinastine is produced by reacting 5H-dibenz[b, e]azepine-6,11-dihydro-6-methanamine with an N-(iminoalkoxymethyl)carbamic ac...
|
|
JP6004884B2 |
|
|
JP6002155B2 |
Compounds of formula (I) or (II) can modulate the activity of SIP receptors. Compounds of formula (I) or (II) can modulate the activity of SIP receptors.
|
|
JP6003755B2 |
|
|
JP5989674B2 |
A thionating agent which is crystalline P 2 S 5 ยท2 C 5 H 5 N.
|
|
JP5985509B2 |
Provided are benzazepine derivatives useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The benzazepine derivatives have use in treating or preventing disease, including cancer, autoimmune disease, fibro...
|
|
JP5985510B2 |
Provided are compounds of formula (II) useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compounds have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease,...
|
|
JP5968466B2 |
An object of the present invention is to provide a compound having a V2 receptor agonistic activity. Provided is a pharmaceutical composition which contains, as an active ingredient, a compound represented by the general formula (I) desc...
|
|
JP2016138122A |
To provide a low molecular weight compound being an antagonist of chemokine receptor function.The method comprises administering to a subject an effective amount of a compound represented by formulas (I) and (II) or physiologically accep...
|
|
JP5963140B2 |
|
|
JP5957016B2 |
A compound having the structure useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, e...
|
|
JP2016128488A |
To provide inhibitors of cyclophilins having a selective inhibition activity for cyclophilin, for its use in the prevention and/or the treatment of viral pathologies or infections.The present invention relates to a compound represented b...
|
|
JP5947724B2 |
The present invention relates to a compound of formula (I): wherein: n is 0, 1 or 2; A is in particular CH or N; X is in particular CO, SO2, CS, and R1 is in particular H, R2 is a group of formula NR3R4 or OR5, R3 and R4 being in particu...
|
|
JP5947998B2 |
wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
|
|
JP5944825B2 |
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. X in formula (I) is selected from -OCF 3 and -OCH 3 . The other variables for Structural Formula (I) ar...
|
|
JP5936669B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ...
|
